VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: Histologically confirmed incurable primary or metastatic solid tumor or non-Hodgkin's lymphoma Relapsed after or is refractory (e.g., unresectable) to at least 2 standard chemotherapy regimens and rituximab No standard curative surgery, chemotherapy, immunotherapy, other antitumor therapy, or radiotherapy options exist No known or suspected squamous cell carcinoma of the lung No prior or concurrent CNS (brain or leptomeningeal) metastases No prior or concurrent primary intracranial tumor by MRI or CT scan PATIENT CHARACTERISTICS: Age: 25 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm^3 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 9.0 g/dL No other severe or uncontrolled hematologic condition Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST and ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN PT, PTT, and INR normal Renal: Creatinine no greater than ULN No 1+ or greater proteinuria No other severe or uncontrolled renal condition Cardiovascular: Electrocardiogram normal LVEF normal by echocardiogram or MUGA scan within the past 12 months or since completion of prior anthracycline No severe or uncontrolled cardiovascular condition No New York Heart Association class III or IV heart disease No active coronary artery disease, angina, congestive heart failure, or arrhythmia No myocardial infarction within the past 6 months No prior or concurrent peripheral vascular disease, including: Angiographically or ultrasonographically documented arterial or venous occlusive event Symptomatic claudication No untreated or uncontrolled hypertension No treated blood pressure more than 160/100 mm Hg on at least 3 repeated determinations on separate days within the past 6 weeks No symptomatic orthostatic hypotension Pulmonary: No severe or uncontrolled pulmonary condition No pulmonary embolism Other: No prior hypersensitivity reactions to any recombinant proteins (e.g., VEGF Trap) No severe or uncontrolled gastrointestinal, immunological, or musculoskeletal condition No severe or uncontrolled psychiatric or adverse social circumstance that would preclude study No active infection requiring antibiotics HIV negative Not pregnant or nursing Negative pregnancy test Fertile patients must use effective double-barrier contraception during and for at least 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 3 weeks since prior immunotherapy No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF) Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy Endocrine therapy: No concurrent adrenal corticosteroids, except low doses as replacement therapy in patients who have previously received suppressive doses or for adrenal insufficiency No concurrent systemic hormonal contraceptive agents Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy Surgery: See Disease Characteristics At least 3 weeks since prior surgery (except fine needle biopsy/aspiration or removal/biopsy of a skin lesion) No prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events Other: Recovered from prior therapy At least 6 months since prior treatment for acute congestive heart failure At least 30 days since prior investigational drugs No concurrent standard or other investigational anticancer agents No concurrent herbal supplements ("nutraceuticals") No concurrent anticoagulant or antiplatelet drugs, (e.g., warfarin, heparin, aspirin, or other non-steroidal anti-inflammatory drugs) except selective cyclo-oxygenase-2 (COX-2) inhibitors for analgesia No concurrent COX-2 inhibitors for tumor treatment or prophylaxis